Fundraising Fox
Reselute
Durham, US · Founded 2021 · Delaware corporation · 3 known investors
Find your way into Reselute
Sign up to see every warm intro you have to Reselute
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Reselute team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Reselute is a privately held medical device company developing orthopedic implant systems that combine structural fixation with controlled local drug delivery. Its lead investigational product targets high-risk tibial fractures where infection is a persistent complication, embedding sustained local antibiotic release within a load-bearing implant.
Founders & leadership
Reselute was founded in 2021 by Cambre Kelly.
Board
Investors · 3
How we know: Charlotte Angel Fund's portfolio page · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6.7M disclosed across 4 rounds · 2023–2026
▶$1MraisedJul 2026 · 1 investors · OtherRule 506(b)
- Cambre KellyDirector, Executive Officer
- Andrew BeaverDirector
- Ken GallDirector
- Offering amount
- $4M
- Amount sold
- $1M
- Minimum investment
- $25K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$2.4MraisedApr 2026 · 23 investors · OtherRule 506(b)
- Cambre KellyDirector, Executive Officer
- Andrew BeaverDirector
- Ken GallDirector
- Offering amount
- $4M
- Amount sold
- $2.4M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$2.6MraisedMay 2024 · 30 investors · OtherRule 506(b)
- Cambre KellyExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- Minimum investment
- $10K
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$700KraisedMay 2023 · 15 investors · OtherRule 506(b)
- Ken GallDirector
- Cambre KellyExecutive Officer
- Offering amount
- $700K
- Amount sold
- $700K
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Reselute do?
- Reselute is a privately held medical device company developing orthopedic implant systems that combine structural fixation with controlled local drug delivery. Its lead investigational product targets high-risk tibial fractures where infection is a persistent complication, embedding sustained local antibiotic release within a load-bearing implant.
- Who founded Reselute?
- Reselute was founded by Cambre Kelly in 2021.
- Who are Reselute's investors?
- Reselute's investors include Band of Angels, Charlotte Angel Fund, Duke Capital Partners.
- How much funding has Reselute raised?
- Reselute has disclosed $6.7M raised across 4 rounds.
- Where is Reselute headquartered?
- Reselute is headquartered in Durham, US.